United States-based practice patterns and resource utilization in advanced neuroendocrine tumor treatment

Table 2 Resource utilization by progression state n (%)

	Baseline			Any progression
	All NET	GI/Lung	pNET	All NET	GI/Lung	pNET
Treatments
Chemotherapy1	17 (16.4)	17 (25.0)	0 (0.0)	46 (26.9)	30 (27.0)	16 (26.7)
Targeted therapies2	3 (2.9)	2 (2.9)	1 (2.8)	6 (3.5)	5 (4.5)	1 (1.7)
PRRT	3 (2.9)	3 (4.4)	0 (0.0)	39 (6.1)	5 (4.5)	0 (0.0)
Somatostatin analogs	66 (63.5)	43 (63.2)	23 (63.9)	83 (48.5)	52 (46.9)	31 (51.7)
Surgery	29 (27.9)	17 (25.0)	12 (33.3)	42 (24.6)	26 (23.4)	16 (26.7)
Resources
Hospitalizations	34 (32.7)	23 (33.8)	11 (30.6)	72 (42.1)	44 (39.6)	28 (46.7)
Ultrasound	38 (36.5)	20 (29.4)	18 (50.0)	34 (19.9)	22 (19.8)	12 (20.0)
CT scans (conventional)	62 (59.6)	43 (63.2)	19 (52.8)	109 (63.7)	72 (64.9)	37 (61.8)
CT scans (helical or spiral)	23 (22.1)	15 (22.1)	8 (22.2)	51 (29.8)	33 (29.7)	18 (30.0)
Other imaging3	51 (49.0)	31 (45.6)	20 (55.6)	52 (30.5)	33 (29.7)	19 (31.7)
Biomarkers4	66 (63.4)	44 (64.7)	22 (61.1)	84 (49.1)	55 (49.6)	29 (48.3)
Lab tests5	61 (58.7)	36 (52.9)	25 (69.4)	84 (49.1)	50 (45.1)	34 (56.7)
Study physician visit	102 (98.08)	66 (97.06)	36 (100.00)	165 (96.49)	107 (96.40)	58 (96.67)
Other physician visit	77 (74.04)	50 (73.53)	27 (75.00)	143 (83.62)	92 (82.88)	51 (85.00)

¹Chemotherapy includes 5-fluorouracil, actinomycin-D, capecitabine, carboplatin, cisplatin, cyclophosphamide, dacarbazine, doxorubicin, etoposide, gemcitabine, irinotecan, mitotane, oxaliplatin, streptozocin, temozolomide and vincristine;

²Targeted Therapy includes everolimus, sunitinib, imatinib, and bevacizumab; the data collection form captured these therapies under the heading “other treatments”;

³Other imaging includes positron emission tomography, stereotactic radiosurgery, metaiobenzylguanidine, magnetic resonance imaging, and chest X-ray;

⁴Biomarkers include neurotensin, chromogranin A, pancreatic polypeptide, neurotensin, plasma serotonin, vasoactive intestinal polypeptide, ghrelin, human chorionic gonadotropin, Ki-67, 5-hydroxyndoleacetic acid, plasma substance P, total and free T4;

⁵Other lab tests include serum glucose, complete blood count, blood urea nitrogen, serum creatinine, and lipid profile were captured. PRRT: Peptide-receptor radionuclide therapy; NET: Neuroendocrine tumor; pNET: Pancreatic NET; GI: Gastrointestinal tract; CT: Computed tomography.